Adrenocortical Carcinoma (ACC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

Adrenocortical Carcinoma (ACC) Market Outlook

Thelansis’s “Adrenocortical Carcinoma (ACC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Adrenocortical Carcinoma (ACC) treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Adrenocortical Carcinoma (ACC) Overview

Adrenocortical carcinoma (ACC) is rare cancer that affects the adrenal gland and primarily affects individuals in early adulthood and between the ages of 40-50. Women are more commonly affected, comprising 55-60% of cases. The majority of ACC cases are of sporadic origin. However, they can also develop as part of familial diseases such as Beckwith-Wiedeman syndrome, Li-Fraumeni syndrome, Lynch syndrome, multiple endocrine neoplasia (MEN), and familial adenomatous polyposis (FAP). There are three main clinical presentations of ACC: hormone excess symptoms and signs in 40-60% of patients, non-specific symptoms due to local tumor growth such as abdominal or flank pain, abdominal fullness, or early satiety in a third of patients. Although the specific genetic alterations involved in ACC development are currently unknown, chromosomal abnormalities have been identified in hereditary neoplasia syndromes. The Wnt/β-catenin constitutive activation and insulin growth factor 2 (IGF2) overexpression are the most important implicated genetic pathways. The protein steroidogenic factor 1 (SF1) plays a significant role in adrenal development and is often overexpressed in ACC. Treatment of ACC requires a multidisciplinary approach, with initial surgical resection in limited disease (stages I, II, and occasionally III). Mitotane (1,1-dichloro-2(o-chlorophenyl)-2-(p-chlorophenyl)ethane [o,p’DDD]) is the only currently available adrenolytic medication, achieving an overall response rate of approximately 30%. The five-year survival rate for ACC varies depending on the presentation stage, with the ENSAT system reporting rates of 82% for stage I, 61% for stage II, 50% for stage III, and 13% for stage IV.

• In the USA, adrenocortical carcinoma annual incidence is estimated to be 1.02 per one million population.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2022-2032

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: